Sign in

You're signed outSign in or to get full access.

Paul Heary

Chief Financial Officer at TAYLOR DEVICES
Executive

About Paul Heary

Paul M. Heary is Chief Financial Officer of Taylor Devices, Inc., appointed effective January 1, 2023 (joined the company September 2022). He is 55 years old in the 2025 proxy and holds BS (Accounting) and MBA degrees from SUNY Buffalo; he previously held CPA and CMA certifications . During his tenure, Taylor Devices’ financial performance has remained robust: FY 2023–FY 2025 revenues rose from $40.2M to $46.3M*, EBITDA from $8.3M to $11.4M*, and net income from $6.3M to $9.4M*, while the company-disclosed TSR index (value of a fixed $100 investment) moved from $198 (FY 2023) to $526 (FY 2024) to $393 (FY 2025) . Values with asterisk retrieved from S&P Global.*

Past Roles

OrganizationRoleYearsStrategic Impact
Multisorb Filtration GroupChief Financial Officer2016–2022Guided company through sale by private equity owner in 2018; led finance for leader in sorbent technology serving pharma, food, industrial markets .
Carleton Technologies (d.b.a. Cobham Mission Systems)Senior Finance Director2006–2016Senior finance leadership at aerospace/defense technology leader; prior roles at Carleton included engineering/business development in broader management context .

External Roles

OrganizationRoleYearsStrategic Impact
Multisorb Filtration GroupChief Financial Officer2016–2022Key finance lead through strategic sale; operational oversight in active packaging industry .
Carleton Technologies (d.b.a. Cobham Mission Systems)Senior Finance Director2006–2016Finance leadership supporting growth and operations at defense contractor .

Fixed Compensation

MetricFY 2023FY 2024FY 2025
Salary ($)$165,000 $231,000 $238,000
Contracted Base Salary ($, Employment Agreement)$238,000 (agreement baseline) $245,140 (updated)
  • Employment Agreement: auto-renews annually; base salary set by Board discretion; eligible for incentive bonus based on Company performance .
  • Initial on-boarding terms (Jan 2023 8‑K): base salary $220,000; eligible for management bonus policy and annual 7,000-share stock option award .

Performance Compensation

Incentive TypeMetricWeightingTargetActualPayoutVesting
Annual Cash Bonus (FY 2023)Company net income pool (aggregate ≤15% of net income across participants)Not disclosedNot disclosed$116,135 Cash
Annual Cash Bonus (FY 2024)Company net income pool (aggregate ≤15%)Not disclosedNot disclosed$237,054 Cash
Annual Cash Bonus (FY 2025)Company net income pool (aggregate ≤15%)Not disclosedNot disclosed$150,981 Cash
Stock Options (Grant 2023)Fixed annual grantN/A7,000 options7,000 @ $19.955 (grant-date 4/18/2023)Grant-date FV $47,017 Exercisable; expires 4/18/2033
Stock Options (Grant 2024)Fixed annual grantN/A7,000 options7,000 @ $46.9926 (4/18/2024)Grant-date FV $121,433 Exercisable; expires 4/18/2034
Stock Options (Grant 2025)Fixed annual grantN/A7,000 options7,000 @ $30.55 (fixed grant date 4/18/2025)Grant-date FV $79,980 Exercisable; expires 4/18/2035
  • Management Bonus Policy cap: the Compensation Committee may approve aggregate bonus payments up to 15% of fiscal-year net income .
  • Option timing policy: grants occur on a fixed schedule (April 18), priced at fair market value; CFO included alongside directors; policy avoids timing around MNPI .

Equity Ownership & Alignment

As-of DateShares Owned% of OutstandingOptions ExercisableOptions Unexercisable
Aug 26, 202422,820 0.69% 14,000 0
Aug 18, 202529,820 0.89% 21,000 0
  • Shares outstanding: 3,118,627 (record date Aug 26, 2024) and 3,147,193 (record date Aug 18, 2025), per proxy .
  • Hedging policy: company prohibits hedging and derivative trading by directors and officers; no pledging disclosure identified .

Option Schedule Detail (Exercisable)

TrancheSharesExercise PriceGrant DateExpiration
2023 Grant7,000 $19.9550 04/18/2023 (plan schedule) 04/18/2033
2024 Grant7,000 $46.9926 04/18/2024 04/18/2034
2025 Grant7,000 $30.5500 04/18/2025 04/18/2035

Employment Terms

  • Effective dates and role: appointed CFO January 1, 2023; joined September 2022 .
  • Agreement structure: auto-renewal each year; either party may decline renewal with 90 days’ notice before term end .
  • Severance: if terminated without Cause (or non-renewal by Company), 12 months base salary continuation plus up to 12 months COBRA premium reimbursement; no severance if non-renewal by executive .
  • Restrictive covenants: 12-month non-compete post-termination in geographies where the Company made sales in prior five years .
  • Base salary under agreement: $238,000 (2024 proxy baseline) and updated to $245,140 (2025 proxy baseline) .
  • Clawback: awards subject to Company’s Recovery of Erroneously Awarded Compensation policy and applicable exchange rules .
  • D&O insurance and indemnification: company maintains D&O coverage and indemnity agreements with expense advancement .

Company Performance (context for pay-for-performance)

MetricFY 2023FY 2024FY 2025
Revenues ($)$40,199,354*$44,582,807*$46,292,725*
EBITDA ($)$8,281,521*$11,177,065*$11,358,399*
Net Income ($)$6,287,358*$8,998,762*$9,413,136*

Values retrieved from S&P Global.*

  • Pay vs Performance TSR index (value of fixed $100 investment): $198 (FY 2023), $526 (FY 2024), $393 (FY 2025) .

Related Party Transactions and Governance

  • Related party transactions: none required to be disclosed for fiscal 2025; none disclosed for fiscal 2024 .
  • Compensation Committee: independent directors Carey, Burgess, Armenat; met three times in FY 2025 and FY 2024; administers stock option plans .

Risk Indicators & Red Flags

  • Hedging/derivatives prohibited for insiders (reduces misalignment risk); no pledging disclosure identified .
  • No repricing allowed under stock option plan without shareholder approval (limits shareholder-unfriendly practices) .
  • Section 16(a) compliance timely for FY 2025 and FY 2024 (reduces disclosure risk) .

Investment Implications

  • Pay-for-performance alignment: CFO cash bonus is tied to a pool capped at 15% of Company net income; equity is granted via fixed annual stock options at FMV with immediate exercisability and long-dated expirations, linking upside to shareholder returns while avoiding repricing and timing games .
  • Retention risk: Employment agreement features modest severance (12 months base salary + COBRA) and a 12-month non-compete; no disclosed CIC cash multiples, suggesting limited parachute economics and good governance balance .
  • Ownership alignment: Heary holds 0.89% of outstanding shares (including 21,000 exercisable options), with no hedging permitted and no pledging disclosed—supportive of alignment; near-term selling pressure appears low given 2033–2035 expirations, though exercises may occur if options are in-the-money .
  • Execution track record: Prior CFO role during a successful PE-backed sale (Multisorb) and senior finance leadership in aerospace/defense provide relevant expertise for cost control and capital allocation in TAYD’s niche industrial markets .